BioCryst to Report Fourth Quarter 2022 Financial Results on February 21

Rhea-AI Summary

BioCryst Pharmaceuticals (Nasdaq: BCRX) announces it will report Q4 2022 financial results on February 21, 2023. The management will host a conference call at 8:30 a.m. ET to discuss results and provide a corporate update. Investors can access the live call by dialing 1-866-777-2509 (domestic) or 1-412-317-5413 (international). A live webcast and replay will be available on the company’s website. BioCryst focuses on developing oral, small-molecule medicines for rare diseases with significant unmet medical needs, including products like ORLADEYO® and RAPIVAB®.

RESEARCH TRIANGLE PARK, N.C., Feb. 07, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its fourth quarter 2022 financial results on Tuesday, February 21, 2023.

BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update.

The live call may be accessed by dialing 1-866-777-2509 for domestic callers and 1-412-317-5413 for international callers. A live webcast and replay of the call will be available online at the investors section of the company website at www.biocryst.com.

About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO^® (berotralstat) is approved in the United States and many global markets. BioCryst has active programs to develop oral medicines for multiple targets across the complement system, including BCX10013, an oral Factor D inhibitor in clinical development. RAPIVAB^® (peramivir injection) is approved in the U.S. and multiple global markets, with post-marketing commitments ongoing. For more information, please visit the company’s website at www.biocryst.com.

BCRXW

Investor Contact:
John Bluth
+1 919 859 7910
jbluth@biocryst.com

Media Contact:
Catherine Collier Kyroulis
+1 917 886 5586
ckyroulis@biocryst.com

FAQ

When will BioCryst Pharmaceuticals report its Q4 2022 earnings?

BioCryst Pharmaceuticals will report its Q4 2022 financial results on February 21, 2023.

What time is the BioCryst Pharmaceuticals earnings call?

The earnings call for BioCryst Pharmaceuticals is scheduled for 8:30 a.m. ET on February 21, 2023.

How can I access the BioCryst Pharmaceuticals earnings call?

You can access the live call by dialing 1-866-777-2509 for domestic callers or 1-412-317-5413 for international callers.

Where can I find the webcast for BioCryst Pharmaceuticals' earnings call?

The live webcast and replay of the earnings call will be available in the investors section of BioCryst Pharmaceuticals' website.

What does BioCryst Pharmaceuticals focus on in its drug development?

BioCryst Pharmaceuticals focuses on discovering oral, small-molecule medicines for rare diseases with significant unmet medical needs.